Maze Therapeutics Inc
MAZEHealthcare|Biotechnology|USA
$30.56
-1.89 (-5.82%)
Tangible Book
$6.87
About
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Stock Price
+95.4%(1Y)
Pipeline Summary
3 total trials1
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2Completed: 1
Active Trials (2)
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT06830629Proteinuric Kidney Disease
Phase 2Recruiting
Enrollment: 56 participants
A Phase 2 Study of MZE782 in Adults With PKU
NCT07694440Phenylketonuria (PKU)
Phase 2Recruiting
Enrollment: 38 participants
BioScore
4.5/10
Cautious
Ownership
Recent Insider Trades
Bernstein HaroldSELL
2026-07-0114,609 shares @ $29.9
Coloma Jason VSELL
2026-07-0134,501 shares @ $29.98
Dandekar AtulSELL
2026-06-297,500 shares @ $28.02
Coloma Jason VSELL
2026-06-2327,858 shares @ $26.04
Bernstein HaroldSELL
2026-06-0114,853 shares @ $25.66
Data last updated: Jul 13, 2026, 12:46 PM